Unknown

Dataset Information

0

Understanding CD8+ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.


ABSTRACT: The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1126-134 (RMFPNAPYL) (HLA-A2/RMFPNAPYL epitope (WT1A)) and its modified variant YMFPNAPYL (HLA-A2/YMFPNAPYL epitope (WT1B)), can induce WT1-specific CD8+ T cells, although WT1B is more stably bound to HLA-A*02:01. Here, to further determine the benefits of those two targets, we assessed the naive precursor frequencies; immunogenicity and cross-reactivity of CD8+ T cells directed toward these two WT1 epitopes. Ex vivo naive WT1A- and WT1B-specific CD8+ T cells were detected in healthy HLA-A*02:01+ individuals with comparable precursor frequencies (1 in 105-106) to other naive CD8+ T-cell pools (for example, A2/HIV-Gag77-85), but as expected, ~100 × lower than those found in memory populations (influenza, A2/M158-66; EBV, A2/BMLF1280-288). Importantly, only WT1A-specific naive precursors were detected in HLA-A2.1 mice. To further assess the immunogenicity and recruitment of CD8+ T cells responding to WT1A and WT1B, we immunized HLA-A2.1 mice with either peptide. WT1A immunization elicited numerically higher CD8+ T-cell responses to the native tumor epitope following re-stimulation, although both regimens produced functionally similar responses toward WT1A via cytokine analysis and CD107a expression. Interestingly, however, WT1B immunization generated cross-reactive CD8+ T-cell responses to WT1A and could be further expanded by WT1A peptide revealing two distinct populations of single- and cross-reactive WT1A+CD8+ T cells with unique T-cell receptor-?? gene signatures. Therefore, although both epitopes are immunogenic, the clinical benefits of WT1B vaccination remains debatable and perhaps both peptides may have separate clinical benefits as treatment targets.

SUBMITTER: Nguyen TH 

PROVIDER: S-EPMC5382434 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Understanding CD8<sup>+</sup> T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.

Nguyen Thi Ho TH   Tan Amabel Cl AC   Xiang Sue D SD   Goubier Anne A   Harland Kim L KL   Clemens E Bridie EB   Plebanski Magdalena M   Kedzierska Katherine K  

Clinical & translational immunology 20170317 3


The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1<sub>126-134</sub> (<b>R</b>MFPNAPYL) (HLA-A2/RMFPNAPYL epitope (WT1A)) and its modified variant <b>Y</b>MFPNAPYL (HLA-A2/YMFPNAPYL epitope (WT1B)), can induce WT1-specific CD8<sup>+</sup> T cells, although WT1B is more stably bound to HLA-A*02:01. Here, to further determine the b  ...[more]

Similar Datasets

| S-EPMC8100314 | biostudies-literature
| S-EPMC6593292 | biostudies-literature
| S-EPMC7533701 | biostudies-literature
| S-EPMC8660260 | biostudies-literature
| S-EPMC5685222 | biostudies-literature
| S-EPMC5407724 | biostudies-literature
| S-EPMC6898063 | biostudies-literature
| S-EPMC8132304 | biostudies-literature
| S-EPMC5190022 | biostudies-literature
| S-EPMC7825995 | biostudies-literature